Call for Papers: Nano‑Micro Tech Drives Regenerative Medicine
🚀 Call for Papers | Special Issue in Frontiers in Bioengineering and Biotechnology Nano–Microtechnology Enabled Immuno-Engineering and Multiscale Fabrication for Next-Generation Regenerative Medicine Join us in shaping the future of regenerative medicine at the convergence of nanotechnology, immuno-engineering, advanced biomaterials, and translational biofabrication. This Special Issue explores groundbreaking innovations in: https://t.co/oFxLLUPOfk 🔬 Nanomaterials & Nano-Microstructured Scaffolds 🧬 Nanoparticle-Mediated Delivery Platforms 🧪 3D Engineered Scaffolds & Dynamic Bioreactor Systems 🧠 Multimodal Imaging & Immunomodulatory Integration 🦴 Musculoskeletal and Complex Tissue Regeneration Models We welcome original research, reviews, and perspective articles that push the boundaries of: Immunomodulatory biomaterials Smart nanoparticle functionalization Microphysiological systems Advanced in vitro platforms Translational regenerative strategies 📢 Why Submit? High visibility in a leading open-access journal Cross-disciplinary impact across bioengineering, nanomedicine, and translational medicine Rigorous peer review and rapid publication Led by an expert international Guest Editorial team If your research bridges materials science, cell biology, immunology, and clinical translation, this Special Issue is your platform to accelerate impact. 🌍 Be part of the next wave of bioengineered re
Alumni Share Timmerman Traverse Experience – Join Now
Join the Timmerman Traverse. WATCH alumni Ted Love, Amy Abernethy, Doug Fambrough and Bonnie Anderson. https://t.co/49ZC5b4mKy
Tirzepatide Delivers up to 21% Weight Loss, Dose‑dependent
Tirzepatide: In the SURMOUNT-1 trial, weight reduction percentages were dose-dependent: 5 mg: ~15.0% weight reduction. 10 mg: ~19.5% weight reduction. 15 mg: ~20.9% weight reduction (Jastreboff et al., 2022). https://www.nejm.org/doi/10.1056/NEJMoa2206038 https://www.gatlan.com/ @GatlanHealth 
Prime Medicine Pursues Approval After Two-Patient Gene Editing Trial
Prime Medicine $PRME to seek approval for gene editing treatment after two-patient trial https://t.co/nBnrUzqSCN via @Jasonmmast
Pierre Fabre Pushes to Revive US Cell Therapy Approval
Pierre Fabre seeks to revive US approval chances for spurned cell therapy https://t.co/gJeklT8asd @ByJonGardner $ATRA $QURE $RGNX
FDA Guidance Boosts Biotech, HHS Calls It Fake
Did the FDA’s individualized therapy guidance put a spike in the heart of a startup biotech? Fake news, says the HHS. Yeah, it did, says an insider. Exclusive from @RLCscienceboss and @Jared_Whitlock https://t.co/IN9o4VIp03
LLM Medical Research Overwhelmingly Lacks Real Clinical Data
A new systematic review of LLMs in medicine @NatureMedicine @ekoermann https://t.co/npvDeqUvel “Despite thousands [4,609] of publications since late 2022, only a small fraction use real clinical data and just 19 randomized trials exist.”
Integrating Omics Data, Not Algorithms, Is Pharma’s Biggest Challenge
The hardest problem in pharma data science isn't the algorithm. It's getting three different omics datasets to agree with each other. That's exactly what we'll dig into at #ddpeast26 on June 10 in Waltham. I'm joining as a panelist and roundtable moderator....
T‑cell Engagers Offer New Autoimmunity Treatment Opportunity
T-cell engagers for autoimmunity. Listen to Ken Song describe the opportunity as CEO of San Diego-based Candid Therapeutics. Sponsored by @AlphaSenseInc & Dash Bio. https://t.co/Ct2viH00c4
APGE Should Drop OX40 Bispec, It's Just a Black Box
$APGE should can the OX40 bispec IMO. You’re basically just tacking on a black box with that MOA at this point…
NKTR Emerges as Biotech's Most Undervalued Gem
More cases of Kaposi sarcoma for OX40. OX. 40. Is. Done. $SNY still projecting $3-$5B peak sales for Amli is a pipe dream. This value is going to $NKTR. $NKTR is, IMO, the single most undervalued name I...
FDA Doubts QURE Gene Therapy Benefit, Leaks to Media
New reporting from me taking you inside the $QURE - FDA Huntington's gene therapy imbroglio. I spoke to a senior FDA official late yesterday, who told me agency reviewers "are not convinced there’s any therapeutic benefit of the product. If...
AI‑Discovered Gal‑3 Blocker Cuts Inflammation, Boosts Memory in Mice
Alzheimer’s research is increasingly looking beyond plaques and tangles to the brain’s immune response. A study published in Elsevier's Pharmacological Research journal used AI to screen 1.6M compounds for a Galectin-3 (Gal-3) blocker that could cross the brain barrier. In Alzheimer’s-like...
Treatable, Not Curable: Biotech Must Rise Now
"Treatable, not curable" should be a call to arms for any cancer biotech that isn't a grift to step up. Life is so cruel more often than not, but humans are tenacious and unstoppable.
P‑tau 217 Blood Test Outperforms Total P‑tau 217 For
The breakthrough blood test p-tau 217 for risk and diagnosis of Alzheimer's disease is more accurate than total p-tau 217, in a head-to-head comparison using PET imaging https://t.co/faILpVr9Ua https://t.co/lzUgFnFUP5
GLP‑1 Weight‑Loss Drugs Work Better for Women
A systematic RCT analysis of GLP-1 drugs show they are more effective in women than men for weight loss https://t.co/cycwi4nnN5 https://t.co/KOl0FgKaZD
Roche's MS Drug Shows Promise, Approval Still Uncertain
Roche pill succeeds in another MS study, but approval questions linger https://t.co/JY8uZCI5iA @ByJonGardner $RHHBY $SNY
FDA Demands Extra Study for UniQure's Huntington Gene Therapy
UniQure says FDA wants another study of Huntington’s gene therapy https://t.co/1pgFDoE2V9 by @realJacobBell $QURE - 35% #GeneTherapy #Huntingtonsdisease
Biologists Using AI Will Outpace Those Who Don't
1/ AI won't replace you. But a biologist who uses AI will. Especially in bioinformatics, where the questions never stop coming. https://t.co/q2OHzntcoV
AI Pathology for Cancer Markers Hindered by Shortcut Learning
AI of whole slide images for cancer molecular markers is not ready for clinical use due to confounding and biases ("shortcut learning"), supported by multiple examples @natBME https://t.co/zG8uVIxrJf https://t.co/hQ0tjiapIJ
Exercise‑derived Muscle Vesicles Boost Brain Microglia, Improve Cognition
A new mechanism for improved cognitive function from exercise in the Alzheimer's disease model Skeletal muscle EC vesicles interact with the brain and rev up microglia function https://t.co/eZu14YVasY
Aardvark Pauses Pivotal Prader‑Willi Trial over Safety
Safety concerns spur Aardvark to halt key Prader-Willi drug trial https://t.co/PWkOuDMIvo $AARD - 52% $SLNO
Vaccine Pioneer Warns: We’re Heading Downhill.
Stanley Plotkin, known as the “godfather of vaccines,” in an interview with @HelenBranswell: “All I can say is that I’m beginning to regret having lived so long — because we’re going downhill.” https://t.co/A2zcoP2Ghd
Antibody Plus Ozempic Drives Significant Weight Loss
New @NatureMedicine A randomized trial of antibody vs activin type II receptors with or without semaglutide (Ozempic). The antibody, bimagrumab, promotes muscle growth. Marked weight loss with the combination https://t.co/XUK93GTAmA
Veteran Vaccine Pioneer Warns of Eroding Confidence
Stanley Plotkin had a major hand in the development of a number of vaccines in use today; he designed the rubella vaccine. He remembers the world before widespread use of vaccines & knows what's coming as vaccine policy is rewritten...
GENB CEO Describes Emotional Whirlwind Going Public
2March: How did @generate_biomed CEO @mike_nally describe his whirlwind of emotions as his company went public? Read what he and CFO Jason Silvers, MD, JD said about $GENB plus updates on $CASIF, $NVAX, $PMVP & $SRPT in my latest StockWatch...
Future: Real-Time Immune Monitoring Like Glucose Tracking
Someday we'll be able to track our immune system like we do glucose Today @NatBME https://t.co/HFcFiUeyFg Previously @ScienceMagazine https://t.co/EcgBdwGxcd https://t.co/SpoZ5bLtjx
Ozempic Reverses Osteoarthritis Cartilage Damage, Study Shows
I used to teach that osteoarthritis was "wear and tear" — lose weight, take painkillers, wait for a knee replacement. A study just published in Cell Metabolism proved that wrong. Semaglutide (Ozempic) didn't just reduce joint pain in osteoarthritis patients — it...
Flare's GU26 Targets Undruggable PPAR‑γ, Yet Caveats Remain
Who's heard of Flare Therapeutics? #GU26 late-breaker shows promise in hitting "undruggable" PPAR-γ target, with a few major caveats. Via @ApexOnco -> https://t.co/1GepvywtL0
Advocacy Bias Keeps Unproven DMD Therapy, Blocks HD Progress
The Duchenne muscular dystrophy patient & advocacy community keeps a gene therapy and multiple drugs on the US market, stopping the FDA from taking action, despite failed confirmatory clinical trials showing no efficacy and questionable safety. The Huntington's disease patient and...
BiotechTV Welcomes New Contributor Wassim Laroussi
BiotechTV is growing today. I’m happy to welcome @WassimLaroussi3 as our newest contributor. I’ve been impressed with his own videos, and he is going to do some very cool stuff for @BiotechTV. https://t.co/LUcm1sTqGz
FDA Limits NTLA Gene Therapy to Mild Cases, Undermining Demand
$NTLA drug is off hold but now being restricted by the FDA to the least severe/sick patients, which would logically be those least likely to want/need an experimental gene editing therapy. Existing options will dominate. Target/disease selection is a...
MRK's Ovarian Cancer Claim Rejected by FDA, EMA
$MRK claims a survival benefit in ovarian cancer irrespective of PD-L1 status, but FDA & EMA say BS. Via @ApexOnco -> https://t.co/Cld1O7Uuvp #ESGO26
FDA Demands Sham‑controlled Trial for uniQure’s AMT‑130
$QURE AMT-130 update: Still blocked The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the primary evidence of effectiveness required to support a marketing application for...
Vaccine Policy Shifts Spark Resurgence of Deadly Diseases
But also it’s not only measles, pertussis (whooping cough) is also returning, and based on latest ACIP (or what used to be ACIP) stunts, we’ll see rotavirus, meningococcal meningitis, HBV liver cancer, return after that. A public health disaster built...
NMN Restores NAD, Shields Heart via SIRT3
According to ITOA, NAD declines with age, causing epigenetic changes & disease susceptibility In 2010, we showed NAD-dependent enzyme, SIRT3, protects the heart 🐁 New study says NAD precursor NMN protects the heart via SIRT3 in mice fed a Western diet https://www.sciencedirect.com/science/article/pii/S0022316626000842
OpenADMET Releases Massive CYP Assay Datasets for Community AI
OK. Here it is. Over the last year, the @OctantBio and OpenADMET team have been hard at work developing scalable, quantitative, data-rich, and low-cost methods for assessing CYP reactivity and inhibition. The interplay between building a data engine and building...
Ginkgo's 2025 Revenue Far Misses $7.6B Promise
Ginkgo reported full year 2025 revenue of $170M at the end of last week. When it went public at a $15B valuation in 2021, they guided to investors that they’d be adding $7.6B in new business PER YEAR in 2025...
Large cfDNA Methylome Atlas Powers Multi‑Cancer Detection
A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection https://t.co/A6gHwcEzqq https://t.co/mSMcR0a833
Welireg Poised to Broaden Reach per GU26 Data
$MRK Welireg could be about to expand its reach at last. #GU26 data via @ApexOnco with relevance to $RCUS -> https://t.co/k59284INdK
Miami Preps for Biotech Week; BiotechTV Covers Barclays Conference
Looks like Miami is getting ready for biotech week (the week after next). Note: BiotechTV will be broadcasting from the Barclays conference March 10 & 11. https://t.co/ToZH0EgOVz
IL11 Deficiency Causes Female Infertility, Low Weight, Osteoporosis
But note IL11 knockout mice are infertile (females) and have low body weight and some osteoporosis. Still interesting angle though.
Accelerating CAR Engineering Shows Promising Cancer Immunotherapy
Some very good news about engineering our cells vs cancer (accelerating the CAR). A short thread 1. For background, a new 5★ review on cancer immunotherapy @Cancer_Cell https://t.co/1Qz2rCs8I5 https://t.co/sJ6BwaXyjk
Single-Cell Atlas Links Marrow Immune Dysregulation to Myeloma Outcomes
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma https://t.co/5t0M2eX0fB https://t.co/p3kv8LEzrC
Tylenol Not Linked to Autism Genes, Study Shows
There are a few known chemical exposures in early pregnancy that interact with autism genes. But not Tylenol. I’ve spoken to RFK Jr about them but he had no interest, and he can’t process scientific information. Here’s my article https://t.co/pxLaDLInlf
Generate Biomed IPO Marks AI‑Driven Protein Breakthrough
This morning @generate_biomed celebrated its IPO on the @NasdaqExchange. We founded Generate at @FlagshipPioneer in 2018, asking: What if we could generate novel protein therapeutics using generative AI tools – without relying on traditional trial-and-error discovery? Today’s IPO is a major...
NKTR Overlooked: Continuous Positives Signal Strong Buying Opportunity
$NKTR is not getting a *fraction* of the credit it deserves. One positive development after another, and the stock simply cannot break out. Look at all that has happened since the stock was at these same levels 2...
Comparing Lorigerlimab, Volrustomig, Cadonilimab: Design Lessons
An intriguing tale of three cities. How do the PD1xCTLA4 bispecific agents lorigerlimab, volrustomig, and cadonilimab stack up when it comes to design and performance? Some useful and pointed lessons here for biotech execs: https://t.co/xaSW15Fvdl https://t.co/dhXbiI3N6v
Atrium Launches to Tackle Rare Heart Diseases with RNA
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA https://t.co/xLp2oQDHGy $RNA $NVS #startups
De Novo Proteins Expected in Clinics Within Two Years
“The era of de novo proteins is coming a lot faster than probably people recognize,” Generate's CEO Mike Nally tells me. “I think within the next year or two you’ll start seeing de novo designs enter the clinic.” https://t.co/u3WQcDD3jL